vs

Side-by-side financial comparison of Enact Holdings, Inc. (ACT) and Organogenesis Holdings Inc. (ORGO). Click either name above to swap in a different company.

Enact Holdings, Inc. is the larger business by last-quarter revenue ($312.7M vs $225.6M, roughly 1.4× Organogenesis Holdings Inc.). On growth, Organogenesis Holdings Inc. posted the faster year-over-year revenue change (78.1% vs 3.6%). Over the past eight quarters, Organogenesis Holdings Inc.'s revenue compounded faster (43.2% CAGR vs 3.6%).

Enact Holdings, Inc. is a leading U.S.-based private mortgage insurance provider. It delivers risk mitigation solutions to residential mortgage lenders, banks, and credit unions, enabling borrowers with smaller down payments to access affordable home financing, and supports sustainable homeownership for diverse consumer groups across the United States.

Organogenesis Holdings Inc. is a leading regenerative medicine firm specializing in developing and manufacturing advanced therapeutic products for wound care, surgical repair, sports medicine, and dermatology. It serves healthcare providers and patients primarily in the U.S. and select international markets, offering clinically validated solutions for unmet medical needs.

ACT vs ORGO — Head-to-Head

Bigger by revenue
ACT
ACT
1.4× larger
ACT
$312.7M
$225.6M
ORGO
Growing faster (revenue YoY)
ORGO
ORGO
+74.5% gap
ORGO
78.1%
3.6%
ACT
Faster 2-yr revenue CAGR
ORGO
ORGO
Annualised
ORGO
43.2%
3.6%
ACT

Income Statement — Q4 FY2025 vs Q4 FY2025

Metric
ACT
ACT
ORGO
ORGO
Revenue
$312.7M
$225.6M
Net Profit
$43.7M
Gross Margin
Operating Margin
71.3%
28.1%
Net Margin
19.4%
Revenue YoY
3.6%
78.1%
Net Profit YoY
469.5%
EPS (diluted)
$1.23
$0.31

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
ACT
ACT
ORGO
ORGO
Q4 25
$312.7M
$225.6M
Q3 25
$311.5M
$150.9M
Q2 25
$304.9M
$101.0M
Q1 25
$306.8M
$86.7M
Q4 24
$301.8M
$126.7M
Q3 24
$309.6M
$115.2M
Q2 24
$298.8M
$130.2M
Q1 24
$291.6M
$110.0M
Net Profit
ACT
ACT
ORGO
ORGO
Q4 25
$43.7M
Q3 25
$21.6M
Q2 25
$-9.4M
Q1 25
$-18.8M
Q4 24
$7.7M
Q3 24
$12.3M
Q2 24
$-17.0M
Q1 24
$-2.1M
Gross Margin
ACT
ACT
ORGO
ORGO
Q4 25
Q3 25
Q2 25
Q1 25
72.6%
Q4 24
75.5%
Q3 24
76.7%
Q2 24
77.6%
Q1 24
73.9%
Operating Margin
ACT
ACT
ORGO
ORGO
Q4 25
71.3%
28.1%
Q3 25
67.4%
13.7%
Q2 25
70.4%
-12.5%
Q1 25
68.9%
-30.9%
Q4 24
68.9%
8.1%
Q3 24
74.1%
5.4%
Q2 24
78.6%
-10.7%
Q1 24
70.6%
-3.5%
Net Margin
ACT
ACT
ORGO
ORGO
Q4 25
19.4%
Q3 25
14.3%
Q2 25
-9.3%
Q1 25
-21.7%
Q4 24
6.1%
Q3 24
10.7%
Q2 24
-13.1%
Q1 24
-1.9%
EPS (diluted)
ACT
ACT
ORGO
ORGO
Q4 25
$1.23
$0.31
Q3 25
$1.10
$0.11
Q2 25
$1.11
$-0.10
Q1 25
$1.08
$-0.17
Q4 24
$1.05
$0.05
Q3 24
$1.15
$0.09
Q2 24
$1.16
$-0.13
Q1 24
$1.01
$-0.02

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
ACT
ACT
ORGO
ORGO
Cash + ST InvestmentsLiquidity on hand
$582.5M
$93.7M
Total DebtLower is stronger
$744.5M
Stockholders' EquityBook value
$5.4B
$300.1M
Total Assets
$6.9B
$598.7M
Debt / EquityLower = less leverage
0.14×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
ACT
ACT
ORGO
ORGO
Q4 25
$582.5M
$93.7M
Q3 25
$545.6M
$63.7M
Q2 25
$616.0M
$73.1M
Q1 25
$639.0M
$110.0M
Q4 24
$602.8M
$135.6M
Q3 24
$674.9M
$94.3M
Q2 24
$711.3M
$89.9M
Q1 24
$624.3M
$88.6M
Total Debt
ACT
ACT
ORGO
ORGO
Q4 25
$744.5M
Q3 25
$744.1M
Q2 25
$743.8M
Q1 25
$743.4M
Q4 24
$743.0M
Q3 24
$742.7M
$62.3M
Q2 24
$742.4M
$63.8M
Q1 24
$746.1M
$65.2M
Stockholders' Equity
ACT
ACT
ORGO
ORGO
Q4 25
$5.4B
$300.1M
Q3 25
$5.3B
$255.1M
Q2 25
$5.2B
$233.2M
Q1 25
$5.1B
$242.9M
Q4 24
$5.0B
$262.9M
Q3 24
$5.0B
$278.5M
Q2 24
$4.8B
$263.5M
Q1 24
$4.7B
$278.0M
Total Assets
ACT
ACT
ORGO
ORGO
Q4 25
$6.9B
$598.7M
Q3 25
$6.9B
$509.8M
Q2 25
$6.8B
$461.1M
Q1 25
$6.7B
$467.4M
Q4 24
$6.5B
$497.9M
Q3 24
$6.6B
$446.3M
Q2 24
$6.3B
$443.2M
Q1 24
$6.3B
$458.5M
Debt / Equity
ACT
ACT
ORGO
ORGO
Q4 25
0.14×
Q3 25
0.14×
Q2 25
0.14×
Q1 25
0.15×
Q4 24
0.15×
Q3 24
0.15×
0.22×
Q2 24
0.15×
0.24×
Q1 24
0.16×
0.23×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
ACT
ACT
ORGO
ORGO
Operating Cash FlowLast quarter
$724.5M
$39.4M
Free Cash FlowOCF − Capex
$34.8M
FCF MarginFCF / Revenue
15.4%
Capex IntensityCapex / Revenue
2.1%
Cash ConversionOCF / Net Profit
0.90×
TTM Free Cash FlowTrailing 4 quarters
$-24.5M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
ACT
ACT
ORGO
ORGO
Q4 25
$724.5M
$39.4M
Q3 25
$192.0M
$3.1M
Q2 25
$119.5M
$-32.9M
Q1 25
$226.7M
$-19.9M
Q4 24
$686.3M
$10.9M
Q3 24
$188.1M
$8.7M
Q2 24
$144.7M
$4.7M
Q1 24
$187.3M
$-10.2M
Free Cash Flow
ACT
ACT
ORGO
ORGO
Q4 25
$34.8M
Q3 25
$844.0K
Q2 25
$-36.5M
Q1 25
$-23.6M
Q4 24
$7.6M
Q3 24
$6.1M
Q2 24
$2.9M
Q1 24
$-12.4M
FCF Margin
ACT
ACT
ORGO
ORGO
Q4 25
15.4%
Q3 25
0.6%
Q2 25
-36.1%
Q1 25
-27.2%
Q4 24
6.0%
Q3 24
5.3%
Q2 24
2.2%
Q1 24
-11.3%
Capex Intensity
ACT
ACT
ORGO
ORGO
Q4 25
2.1%
Q3 25
1.5%
Q2 25
3.6%
Q1 25
4.2%
Q4 24
2.7%
Q3 24
2.2%
Q2 24
1.4%
Q1 24
2.0%
Cash Conversion
ACT
ACT
ORGO
ORGO
Q4 25
0.90×
Q3 25
0.14×
Q2 25
Q1 25
Q4 24
1.43×
Q3 24
0.71×
Q2 24
Q1 24

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons